Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $80.00 price target on the biotechnology company's stock. HC Wainwright's price objective would suggest a potential upside of 301.00% from the stock's previous close.

Several other analysts have also recently commented on ARWR. StockNews.com upgraded Arrowhead Pharmaceuticals to a "sell" rating in a report on Friday, December 20th. Chardan Capital restated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Citigroup reduced their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday, November 27th. Royal Bank of Canada reissued an "outperform" rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Finally, Piper Sandler reduced their price objective on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating on the stock in a report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of "Hold" and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Price Performance

ARWR stock traded up $0.84 during trading on Wednesday, hitting $19.95. 930,578 shares of the stock traded hands, compared to its average volume of 2,631,224. The stock has a market cap of $2.50 billion, a price-to-earnings ratio of -3.97 and a beta of 0.95. Arrowhead Pharmaceuticals has a one year low of $17.05 and a one year high of $36.72. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. The company has a 50 day simple moving average of $20.00 and a 200 day simple moving average of $21.05.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). Equities analysts expect that Arrowhead Pharmaceuticals will post -3.4 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Kenneth Allen Myszkowski sold 27,167 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.83, for a total value of $538,721.61. Following the completion of the transaction, the chief financial officer now owns 473,433 shares of the company's stock, valued at $9,388,176.39. The trade was a 5.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the firm's stock in a transaction on Friday, December 27th. The stock was sold at an average price of $20.00, for a total value of $57,000.00. Following the sale, the director now directly owns 36,740 shares in the company, valued at $734,800. The trade was a 7.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 147,432 shares of company stock valued at $2,957,986 over the last three months. Company insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently modified their holdings of the business. World Investment Advisors LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 3.8% during the 3rd quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company's stock valued at $371,000 after purchasing an additional 700 shares in the last quarter. Xponance Inc. lifted its stake in Arrowhead Pharmaceuticals by 4.5% in the fourth quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company's stock valued at $327,000 after buying an additional 744 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company's stock valued at $88,000 after buying an additional 788 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Arrowhead Pharmaceuticals by 2.2% during the fourth quarter. Ameritas Investment Partners Inc. now owns 37,994 shares of the biotechnology company's stock worth $714,000 after acquiring an additional 803 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Arrowhead Pharmaceuticals by 1.5% during the third quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company's stock worth $1,199,000 after acquiring an additional 886 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.